Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea L Harzstark

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Expert Review of Anticancer Therapy|February 19, 2008
Therapies in development for castrate-resistant prostate cancerAndrea L Harzstark, Charles J Ryan
The Oncologist|April 4, 2009
Immunotherapeutics in development for prostate cancerAndrea L Harzstark, Eric J Small
Expert Opinion on Investigational Drugs|December 22, 2007
Novel therapeutic strategies in development for prostate cancerAndrea L Harzstark, Charles J Ryan
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Sipuleucel-T for the treatment of prostate cancerAndrea L Harzstark, Eric J Small
Expert Opinion on Biological Therapy|August 21, 2007
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)Andrea L Harzstark, Eric J Small
Expert Opinion on Pharmacotherapy|March 24, 2010
Castrate-resistant prostate cancer: therapeutic strategiesAndrea L Harzstark, Eric J Small
The Oncologist|November 19, 2020
SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large Integrated Health Care System in Northern CaliforniaArchana Anantharaman, Jennifer R Dusendang, Julie A Schmittdiel, et al.
Cureus|May 17, 2024
Choriocarcinoma Syndrome: A Rare Complication's Impact on Metastatic Germ Cell Tumor OutcomesSanjeev Herr, Razmig Garabet, Lillian Tseng, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Expert Review of Anticancer Therapy|February 19, 2008
Therapies in development for castrate-resistant prostate cancerAndrea L Harzstark, Charles J Ryan
The Oncologist|April 4, 2009
Immunotherapeutics in development for prostate cancerAndrea L Harzstark, Eric J Small
Expert Opinion on Investigational Drugs|December 22, 2007
Novel therapeutic strategies in development for prostate cancerAndrea L Harzstark, Charles J Ryan
Drugs of Today (Barcelona, Spain : 1998)|June 10, 2008
Sipuleucel-T for the treatment of prostate cancerAndrea L Harzstark, Eric J Small
Expert Opinion on Biological Therapy|August 21, 2007
Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)Andrea L Harzstark, Eric J Small
Expert Opinion on Pharmacotherapy|March 24, 2010
Castrate-resistant prostate cancer: therapeutic strategiesAndrea L Harzstark, Eric J Small
The Oncologist|November 19, 2020
SARS-CoV-2 Clinical Outcomes in Patients with Cancer in a Large Integrated Health Care System in Northern CaliforniaArchana Anantharaman, Jennifer R Dusendang, Julie A Schmittdiel, et al.
Cureus|May 17, 2024
Choriocarcinoma Syndrome: A Rare Complication's Impact on Metastatic Germ Cell Tumor OutcomesSanjeev Herr, Razmig Garabet, Lillian Tseng, et al.
Urologic Oncology|October 2, 2010
Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II studyTerence W Friedlander, Vivian K Weinberg, Eric J Small, et al.
Cancer|March 10, 2011
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinomaAndrea L Harzstark, Eric J Small, Vivian K Weinberg, et al.
Pageof 3